In a recent webinar ARMGO Pharma discussed data from the Phase 1b trial of our Rycal® ARM210 (S48168) for the treatment of Ryanodine Receptor 1 Related Myopathies (RYR1-RM), an orphan muscle disease. The event took place on Monday, February 26, 2024 and was organized by the RYR1 Foundation and chaired by the Foundation’s President, Dr. Michael Goldberg. Our CEO and co-author of the study Dr. Gene Marcantonio, was joined by Dr. Payam Mohassel, the principal investigator and Dr. Joshua Todd, the lead associate investigator of the study.